<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014234</url>
  </required_header>
  <id_info>
    <org_study_id>20070034809</org_study_id>
    <nct_id>NCT01014234</nct_id>
  </id_info>
  <brief_title>Rapamycin and Regulatory T Cells in Kidney Transplantation</brief_title>
  <official_title>Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The immune system response is mediated by the interaction between the antigen presenting cell&#xD;
      (APC), CD4+ T helper cells (Th) and CD4+ CD25+ regulatory T cells, a subgroup of CD4+ T cell&#xD;
      which express IL-2 receptor (CD25) and the transcriptional factor foxp3. Regulatory T cell&#xD;
      may contribute to the maintenance of tolerance by suppressing the immune response to normal&#xD;
      or tumor associated antigens.&#xD;
&#xD;
      Regulatory T cell emerge from the thymus during ontogenesis and they represent about 10 % of&#xD;
      the peripheral Cd4+ t cells.&#xD;
&#xD;
      Rapamycin is one the most use treatment to prevent renal allograft failure. Differently from&#xD;
      calcineurin inhibitors (cyclosporine and tacrolimus), that inhibit T-cell activation through&#xD;
      the inhibition of calcineurin activation, rapamycin inhibits cellular proliferation by&#xD;
      impairing the progression of the cellular cycle, in particular by interaction with mTOR.&#xD;
      Recently Battaglia et al. have demonstrated a Treg amplification in murine CD4+ lymphocytes&#xD;
      treated with rapamycin in vitro.&#xD;
&#xD;
      Aim of the study is to evaluate the effect of different immunosuppressive regimens on&#xD;
      regulatory T cell and to verify the hypothesis that rapamycin may induce tolerance in kidney&#xD;
      transplanted patients, more than cyclosporine treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is two years randomised controlled trial in parallel groups.&#xD;
&#xD;
      It has been resolved to compare different immunosuppressive regimens:&#xD;
&#xD;
        1. cyclosporine+ mycophenolate+prednisone&#xD;
&#xD;
        2. rapamycin + mycophenolate + prednisone, this treatment should be introduced after one&#xD;
           month from renal transplantation.&#xD;
&#xD;
      Patient should visited at month 1-6-12-24 from the transplant. During the control we will&#xD;
      reported the following data: physical examination, blood test (blood count, creatinin, BUN,&#xD;
      immunosuppressive blood concentration, histological response of surveillance renal biopsy),&#xD;
      blood pressure, attendant change of current therapy, pathological variation, or any&#xD;
      hospitalisation both ordinary or in DH regimen.&#xD;
&#xD;
      Moreover in all control visit it will be collected a blood sample for evaluation of&#xD;
      regulatory t cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute number of T-reg after renal transplant in patients in treatment with rapamycin compared to patients treated with cyclosporine</measure>
    <time_frame>Every 6 months after the transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events developed during the duration of the clinical study, that damage the patient, that is not part of the natural history of the disease.</measure>
    <time_frame>Every two months during the follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
    <description>These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.</description>
    <arm_group_label>cyclosporine</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female aged from 18 to 75 years&#xD;
&#xD;
          -  Transplanted patients from cadaveric donors&#xD;
&#xD;
          -  Patients who has given written informed consensus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legally unable patients&#xD;
&#xD;
          -  Patients who have been participated to others studies in the last 3 months&#xD;
&#xD;
          -  Addicted to alcohol or smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Dal Canton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Fondazione IRCCS &quot;San Matteo&quot;, Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Fondazione IRCCS &quot;San Matteo&quot;</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006 Dec 15;177(12):8338-47.</citation>
    <PMID>17142730</PMID>
  </reference>
  <reference>
    <citation>San Segundo D, Fernández-Fresnedo G, Ruiz JC, Rodrigo E, Benito MJ, Arias M, López-Hoyos M. Two-year follow-up of a prospective study of circulating regulatory T cells in renal transplant patients. Clin Transplant. 2010 May-Jun;24(3):386-93. doi: 10.1111/j.1399-0012.2009.01086.x. Epub 2009 Sep 11.</citation>
    <PMID>19744094</PMID>
  </reference>
  <reference>
    <citation>Ramírez E, Morales JM, Lora D, Mellado M, Cevey M, Alfaro FJ, De Pablos P, Andrés A, Paz-Artal E, Serrano A. Peripheral blood regulatory T cells in long-term kidney transplant recipients. Transplant Proc. 2009 Jul-Aug;41(6):2360-2. doi: 10.1016/j.transproceed.2009.05.007.</citation>
    <PMID>19715919</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Carmelo Libetta</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immune system regulation</keyword>
  <keyword>Regulatory T cells</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>Tolerance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

